COVID-19 O‘TKAZGAN PARKINSON KASALLIGI BILAN OG‘RIGAN BEMORLARDA INTERLEYKIN-6 MIQDORINING O‘ZGARISH DARAJALARI
##article.subject##:
Covid-19 infeksiyasi, Parkinson kasalligi, “sitokinli shtorm”, interleykin-6, ferritin##article.abstract##
Koronavirus kasalligi (COVID-19) pandemiyasi inson kasalliklarining immunopatologiyasi muammolariga har qachongidan ham ko‘proq e’tibor qaratishni talab etdi, ularning aksariyati neyrodegenerativ kasalliklarni o‘rganishda aks ettirilgan. RNK saqlochi SARS-CoV-2 virusining eng muhim nishon tizimlaridan biri, bu asab tizimi ekanligini aniq ko‘rsatdi. COVID-19 va neyrodegenerativ kasalliklar, jumladan Parkinson kasalligi (PD) o‘rtasidagi munosabatlar alohida qiziqishlarni uyg‘otadi. Parkinson kasalligi, uning klassik ta’rifiga ko‘ra, surunkali, progressiv neyrodegenerativ kasallik hisoblanadi. Hozirgi vaqtda diagnostika qilish faqat motor belgilari (qotib qolish, oligo- va bradikineziya, tinch holatda tremor bo‘lishi) rivojlanishiga binoan aniqlanishi mumkin. Yangi SARS-CoV-2 infeksiyasi neyrotrop xususiyatlarga ega va hozirgi kunga qadar COVID-19 ning boshida va/yoki eng rivojlangan davri fonida deliriy, meningit, ensefalit va oʻtkir koʻndalang mielit rivojlanishi holatlari kuzatildi. Koronavirus xo‘jayin organizmida haddan tashqari, tartibga solib bo ‘lmaydigan immun reaksiyaga - sitokinlar ajralishi sindromiga olib kelishi mumkin. Immunitetning ushbu turi nishon organlar disfunksiyasi rivojlanishining ajralmas qismi va kasallikning asosiy omillaridan biri ekanligi haqida ma’lumotlar tobora ko‘payib bormoqda. Covid-19 o‘tkazgan bemorlarda immunologik mexanizmlar o‘ziga xos bo‘lgan xususiyatlarga ega. Tug‘ma va orttirilgan immunitet hujayralari tomonidan nazorat qilinmaydigan sitokinlarning ishlab chiqarilishi «sitokinli bo‘ron» rivojlanishiga olib keladi. Ushbu ishda Parkinson kasalligida immunologik sitokinlar - interleykin-6 (IL-6) miqdorining o‘zgarishlarini tavsiflaydi. Ushbu ishda Covid-19 infeksiyasining Parkinson kasalligining klinik kechishiga ta’siri, shuningdek, parkinsonizm rivojlanishi uchun xavf omili muhokama qilinadi.
Библиографические ссылки
Zalyalova Z.A., Khasanova D.M. Risk of development and course of COVID-19 in patients with Parkinson's disease. Journal neurol. and a psychiatrist. them. S.S. Korsakov. 2021;121 (9). - C. 152-156. (in Russ).
Zalyalova, S.E. Munasipova, D.M. Khasanova, G.R. Ilyina, Z.G. Khayatova, N.I. Bagdanova, M.M. Ermakova. Parkinson's disease and COVID-19: a new role for amantadines. Results of our own comparative study // Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders. 2022;2;12437-12446. (in Russ).
Illorioshkin S.N. Parkinson's disease in the era of the Covid-19 pandemic // nervous diseases.2021(4); 11-18. (in Russ).
Katunina E.A. Amantadines in the treatment of Parkinson's disease. New opportunities in the context of COVID-19. Journal neurol. and a psychiatrist. them. S.S. Korsakov. 2021;121(4); 101-106. (in Russ).
Umirova, S. M., & Matmurodov, R. J. (2022). Features of early diagnosis and treatment of the diabetic polyneuropathy in adults. medicine new day _ Avicenna-med. uz, 6, 44.
Matmurodov R.J., Umirova S.M., Comparative analysis of clinical-neurological, neurophysiological disorders and complement С3 component in patients with diabetic polyneuropathy who underwent Covid-19 // Journal of neurology and neurosurgery research. 2023(3); 51-55. (in Uzb)
Muminova N.Kh., Visogortseva O.N. Possibility of using traditional medicine methods at the outpatient stage of rehabilitation of patients who have suffered from Covid-19. // Journal of Neurology and Neurosurgical Research. 2022; (5): 59-64(in Russ).
Muminova N.Kh. Visogortseva O.N. Features of rehabilitation programs for patients who have suffered coronavirus infection Covid-19, complicated by psychoneurological disorders // Bulletin of TMA special issue. 2021; 20-23. (in Russ).
Muminova N.H. Boisov S.K. Clinical manifestations of coronavirus infection and psychoneurological complications of patients who have suffered from Covid-19 disease. // International bulletin of medical sciences and clinical research. 2023; (5):74-80. (in Russ).
Matmurodov, R.J., & Umirova, S. M. (2021). Results of the use of combilepene tabsa in the treatment of diabetic polyneuropathy in young people. Journal of cardiorespiratory research. № SI-1. (in Uzb)
Rakhimbaeva G.S., Shodiev U.D. Post-Covid cerebro-asthenic syndrome // Journal of neurology and neurosurgical research. 2021; (2):6-10. (in Russ).
Safarov K.K. Neurological complications of coronavirus infection // Questions of science and education, Ivanovo. 2021;28 (153): 27-40. (in Russ).
Safarov K.K., Khaidarova D.K. Features of the psycho-emotional sphere in patients who have had COVID-19 depending on gender // Journal of Neurology and Neurosurgical Research. 2021; (4): 39-44. (in Russ).
Matmurodov, R. J., & Umirova, S. M. The role of coronavirus infection in the development of diabetic polyneuropathy and its effect on the complement system. Tashkent-2021. Journal of Biomedicine and Practice, 6.
Matmurodov, R. J., & Umirova, S. M. The role of coronavirus infection in the development of diabetic polyneuropathy and its effect on the complement system. Journal of Biomedicine and Practice. 2021/6(3); 256-263. (in Uzb)
Umirova S.M., Matmurodov R.J., Features of early diagnosis and treatment of diabetic polyneuropathies in adult patients // New day journal of medicine. 2022; 6 (44):162-166. (in Uzb)
Khalimova, H. M., Khalimova, Z. Y., Khodjimetov, A. A., Matmurodov, R. J., & Umirova, S. M. (2022). The role and significance of complement C3 factor in the clinical course of diabetic polyneuropathy. American journal of medicine and medical sciences, 12(11), 1166-1170.
Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, Paul JJ, Gaber H, Skrahina V, Bornstein NM, Yahalom G. A case of probable Parkinson’s disease after SARS-CoV-2 infection. The Lancet. Neurology 2020;19(10):804-805.
Cilia R et al. Effects of COVID-19 on Parkinson’s disease clinical features: a community-based case–control study. Mov. Disord. 2020;35(8):1287-1292.
Cilia R, Mancini F, Bloem BR, Eleopra R. Telemedicine for Parkinson ism: a two-step model based on the COVID-19 Expeeience in Milan, Italy. Parkinsonism Relat Disord 2020;75:130–132.
Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID 19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 2020; 38(1):1-9.
Scalzo P. Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neuroscience Letters. 2010;56–58.
Wang Y.-T., Landeras-Bueno S., Hsieh L.-E. et al. Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV2. Trends in Microbiol. 2020; 28(8): 605–618.
Zhang B., Zhou X., Zhu C. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. 2020.
Rizaev , Zh., Raimova , M., Boboev , K., & Abdullaeva, M. (2019). Parkinson's: classification, clinical picture and basics of treatment. Stomatologiya , 1(1(74), 64–67
Zeynitdinova , Z. A. , RIZAEV , J. A. , & Oripov , F. WITH . (2022). The degree of cytological damage to the epithelium of the buccal mucosa in COVID-19. JOURNAL OF BIOMEDICINE AND PRACTICE, 7(2).
Статья поступила в редакцию 03.03.2024; одобрена после рецензирования 20.04.2024; принята к публикации 26.04.2024.
The article was submitted 03.03.2024; approved after reviewing 20.04.2024; accepted for publication 26.04.2024.
Информация об авторах:
Муминов Бекзод Аскарович, Ташкентская медицинская академия. Ташкент, Узбекистан. Е-mail: muminov-bekzod@list.ru, https://orcid.org/0009-0007-2744-9165
Матмуродов Рустамбек Жуманазарович- д.м.н., профессор. Ташкентская медицинская академия. Ташкент, Узбекистан. Е-mail: nevropatolog@mail.ru, https://orcid.org/0000-0003-2666-3286
Халимова Ханифа Мухсиновна- д.м.н., профессор. Ташкентская медицинская академия. Ташкент, Узбекистан. Е-mail: hanifa1948@bk.ru, https://orcid.org/0000-0001-7247-6110
Назарова Мадинабону Фаридовна- магистр, Ташкентская медицинская академия. Ташкент, Узбекистан. Е-mail: m.f.nazarova1217@gmail.com, https://orcid.org/0009-0009-9483-6071
Умирова Сурайё Мамуржоновна- PhD, Самаркандский государственный медицинский университет. Самарканд, Узбекистан. Е-mail: lenuraumirova@gmail.com, https://orcid.org/0009-0001-1538-3791.
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Матмуродов Р.Ж., Халимова Х.М. — идеологическая концепция работы, написание текста; редактирование статьи;
Муминов Б.А., Умирова С.М., Назарова М.Ф. — сбор и анализ источников литературы, написание текста.
Information about the authors:
Muminov Bekzod Askarovich, Tashkent medical academy. Tashkent, Uzbekistan. Е-mail: muminov-bekzod@list.ru, https://orcid.org/0009-0007-2744-9165
Matmurodov Rustambek Jumanazarovich- DSc, Professor. Tashkent medical academy. Tashkent, Uzbekistan. Е-mail: nevropatolog@mail.ru, https://orcid.org/0000-0003-2666-3286
Хаlimova Xanifa Muxsinovna- DSc, Professor. Tashkent medical academy. Tashkent, Uzbekistan. Е-mail: hanifa1948@bk.ru, https://orcid.org/0000-0001-7247-6110
Nazarova Madinabonu Faridovna- master, Tashkent medical academy. Tashkent, Uzbekistan. Е-mail: m.f.nazarova1217@gmail.com, https://orcid.org/0009-0009-9483-6071
Umirova Surayyo Mamurjonovna- PhD, Samarkand state medical university. Samarkand, Uzbekistan. Е-mail: lenuraumirova@gmail.com, https://orcid.org/0009-0001-1538-3791.
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
Contribution of the authors:
Matmurodov R.J., Xalimova X.M.— ideological concept of the work, writing the text; editing the article;
Muminov B.A., Umirova S.M., Nazarova M.F.— collection and analysis of literature sources, writing the text.
